Davita Inc vs Rio Tinto (ADR) — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Rio Tinto (ADR) trades at $94.46 (market cap $150.89B). The key difference: Rio Tinto (ADR) is far larger — about 13.4× Davita Inc's market cap, and Rio Tinto (ADR) pays a 4.98% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Rio Tinto (ADR) for 10 Days on average.
| DVA | RIO | |
|---|---|---|
Market Cap | $11.29B | $150.89B |
Volume | 582,204 | 1,492,444 |
Sector | Health | Basic Materials |
52-Week High | $240.96 | $112.04 |
52-Week Low | $103.87 | $65.44 |
Typical Hold Time | 113 Days | 10 Days |
Enterprise Value | $24.01B | $164.24B |
Dividend Yield | — | 4.98% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →